Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Patrick Oeckl, Steffen Halbgebauer, Sarah Anderl-Straub, Petra Steinacker, Andre M. Hussa, Hermann Neugebauer, Christine A.F. Von Arnim, Janine Diehl-Schmid, Timo Grimmer, Johannes Kornhuber, Piotr Lewczuk, Adrian Danek, Lobar Degeneration, Albert C. Ludolph, Markus Otto

Research output: Contribution to journalArticlepeer-review

170 Scopus citations

Abstract

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

Original languageEnglish
Pages (from-to)481-488
Number of pages8
JournalJournal of Alzheimer's Disease
Volume67
Issue number2
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Alzheimer's disease
  • GFAP
  • Lewy body dementia
  • Parkinson's disease
  • astrocyte
  • biomarker
  • cerebrospinal fluid
  • differential diagnosis
  • frontotemporal dementia
  • serum

Fingerprint

Dive into the research topics of 'Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment'. Together they form a unique fingerprint.

Cite this